Symptoms compatible with functional bowel disorders are common in patients with quiescent ulcerative colitis and influence the quality of life but not the course of the disease.
IBS in ulcerative colitis
functional bowel disorders in ulcerative colitis
inflammation in ulcerative colitis
phychosocial aspects in ulcerative colitis
quality of life in ulcerative colitis
ulcerative colitis
Journal
Therapeutic advances in gastroenterology
ISSN: 1756-283X
Titre abrégé: Therap Adv Gastroenterol
Pays: England
ID NLM: 101478893
Informations de publication
Date de publication:
2019
2019
Historique:
received:
06
09
2018
accepted:
19
12
2018
entrez:
1
3
2019
pubmed:
1
3
2019
medline:
1
3
2019
Statut:
epublish
Résumé
Whether patients with inactive ulcerative colitis (UC) have symptoms compatible with functional bowel disorders (FBDs) other than irritable bowel syndrome (IBS) is unclear. Our aim was to investigate the prevalence and burden of these symptoms and determine impact on the UC course. We used Mayo score, sigmoidoscopy and calprotectin (f-cal) to define remission in 293 UC patients. Presence of symptoms compatible with FBD, severity of gastrointestinal, extraintestinal and psychological symptoms, stress levels and quality of life (QoL) were measured with validated questionnaires. At 1 year later, remission was determined by modified Mayo score and f-cal in 171 of these patients. They completed the same questionnaires again. A total of 18% of remission patients had symptoms compatible with FBD other than IBS, and 45% subthreshold symptoms compatible with FBD. The total burden of gastrointestinal symptoms in patients with symptoms compatible with FBD was higher than in patients without FBD ( Symptoms compatible with FBD other than IBS are common during UC remission influencing patients' QoL but not the UC course.
Sections du résumé
BACKGROUND
BACKGROUND
Whether patients with inactive ulcerative colitis (UC) have symptoms compatible with functional bowel disorders (FBDs) other than irritable bowel syndrome (IBS) is unclear. Our aim was to investigate the prevalence and burden of these symptoms and determine impact on the UC course.
METHODS
METHODS
We used Mayo score, sigmoidoscopy and calprotectin (f-cal) to define remission in 293 UC patients. Presence of symptoms compatible with FBD, severity of gastrointestinal, extraintestinal and psychological symptoms, stress levels and quality of life (QoL) were measured with validated questionnaires. At 1 year later, remission was determined by modified Mayo score and f-cal in 171 of these patients. They completed the same questionnaires again.
RESULTS
RESULTS
A total of 18% of remission patients had symptoms compatible with FBD other than IBS, and 45% subthreshold symptoms compatible with FBD. The total burden of gastrointestinal symptoms in patients with symptoms compatible with FBD was higher than in patients without FBD (
CONCLUSION
CONCLUSIONS
Symptoms compatible with FBD other than IBS are common during UC remission influencing patients' QoL but not the UC course.
Identifiants
pubmed: 30815033
doi: 10.1177/1756284819827689
pii: 10.1177_1756284819827689
pmc: PMC6383088
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1756284819827689Déclaration de conflit d'intérêts
Conflict of interest statement: GM has served as a consultant/advisory board member for Abbvie, Tillotts and Pfizer, and as a speaker for Ferring Pharmaceuticals and Takeda. MS received unrestricted research grants from Danone and Ferring Pharmaceuticals and served as a consultant/advisory board member for AstraZeneca, Danone, Nestle, Almirall, Allergan, Albireo, Glycom and Shire, and as a speaker for Tillotts, Menarini, Takeda, Shire, Allergan and Almirall. BJ has served as consultant/advisory board member and speaker for MSD, Abbvie, Tillotts, MEDA and Takeda. LÖ received unrestricted research grants from AstraZeneca and served as consultant/advisory board member for Genetic Analysis, and as a speaker for Takeda and Abbvie. HS has served as a consultant/advisory board member for Takeda, Abbvie, Ferring Pharmaceuticals, Tillotts, Pfizer, Janssen and MSD, and as a speaker for Takeda, Abbvie, Ferring Pharmaceuticals, Tillotts, MSD and Shire.
Références
Digestion. 2000;62(1):66-72
pubmed: 10899728
Psychosom Med. 2002 Mar-Apr;64(2):258-66
pubmed: 11914441
Can J Gastroenterol. 2005 Sep;19 Suppl A:5A-36A
pubmed: 16151544
Inflamm Bowel Dis. 2006 Jan;12(1):38-46
pubmed: 16374257
Gastroenterology. 2006 Apr;130(5):1377-90
pubmed: 16678553
Gastroenterology. 2006 Apr;130(5):1480-91
pubmed: 16678561
Clin Gastroenterol Hepatol. 2009 Jan;7(1):48-53
pubmed: 18848909
Scand J Gastroenterol. 2009;44(4):431-40
pubmed: 19101844
Am J Gastroenterol. 2010 Aug;105(8):1788, 1789-94; quiz 1795
pubmed: 20389294
Gut. 2010 Jun;59(6):767-74
pubmed: 20551462
Aliment Pharmacol Ther. 2010 Sep;32(6):811-20
pubmed: 20629976
J Gastroenterol Hepatol. 2011 May;26(5):916-23
pubmed: 21214889
Gastroenterology. 2011 Oct;141(4):1293-301, 1301.e1-3
pubmed: 21745450
N Engl J Med. 2011 Nov 3;365(18):1713-25
pubmed: 22047562
Am J Gastroenterol. 2012 Oct;107(10):1474-82
pubmed: 22929759
J Clin Gastroenterol. 2013 Apr;47(4):e38-44
pubmed: 23090047
Aliment Pharmacol Ther. 2013 Jul;38(1):44-51
pubmed: 23668698
Gut. 2014 May;63(5):744-52
pubmed: 23878165
Clin Gastroenterol Hepatol. 2015 Nov;13(11):1929-36.e1
pubmed: 26051392
Aliment Pharmacol Ther. 2015 Nov;42(10):1200-10
pubmed: 26388424
Gastroenterology. 1989 Mar;96(3):804-10
pubmed: 2644154
World J Gastrointest Pharmacol Ther. 2016 Feb 6;7(1):78-90
pubmed: 26855814
Inflamm Bowel Dis. 2016 Nov;22(11):2630-2640
pubmed: 27636379
Nat Rev Gastroenterol Hepatol. 2016 Sep 26;13(10):613-21
pubmed: 27667579
Dig Dis Sci. 1988 Feb;33(2):129-34
pubmed: 3123181
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
J Health Soc Behav. 1983 Dec;24(4):385-96
pubmed: 6668417
Gut. 1983 Mar;24(3):190-2
pubmed: 6826101
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820